Senzime reports initial evaluation from the clinical trial at NorthShore in Chicago, USA
Uppsala, January 23, 2017. Senzime AB (publ) reports initial feedback from the clinical trials at NorthShore University HealthSystem, Chicago, USA, a Teaching Affiliate of the University of Chicago Pritzker School of Medicine. Professor Glenn Murphy is a world-leading clinical investigator and authority in postoperative complications that result from residual neuromuscular block in patients undergoing surgery and general anesthesia. He is the lead investigator of the study that examines the clinical utility of the TetraGraph System, and compares its ease of use, reliability and precision to the TOF-Watch, the former leading neuromuscular monitor that has been discontinued from the market.
Every year over 70 million surgical patients undergo general anesthesia and receive neuromuscular blocking drugs. Without objective monitoring, over 30 percent of these patients experience postoperative complications. Senzime in collaboration with Professor Glenn Murphy is performing a study, investigating the TetraGraph monitor’s accuracy and consistency, while collecting clinician usability data.
Following the first evaluation of TetraGraph after initiation of the study, Dr. Murphy stated, “The use of quantitative neuromuscular monitors has emerged as the most reliable means to manage neuromuscular blockade and mitigate complications. The TetraGraph monitor is a portable and user-friendly EMG-based device that allows quantitative neuromuscular monitoring in settings where motion detection is not possible. I have had the opportunity to use the TetraGraph on several surgical patients. The Tetragraph required minimal setup time, was significantly easier to use than other quantitative monitors, and provided data that was helpful in the management of the anesthetic. The TetraGraph is an important development in a new generation of quantitative monitors that should enhance patient safety."
The first comparative results will be reported later in the first quarter of 2017.
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com